Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTIC: Arterial Infusion Oxaliplatin + S-1 + Sintilimab vs SOX + Sintilimab for Locally Advanced Gastric Cancer
NCT05593458Phase 3Recruiting
- Sponsor
- Zhejiang University
- Start
- Mar 2023
- Primary completion
- Jun 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin in gastric cancer (GC) (2 arms), sponsored by Zhejiang University. Primary endpoint: Major Pathological Response rate at 6 months. Started Mar 2023; status: recruiting.
02
Drugs
oxaliplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05593458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05593458.